Epoetin beta - Chugai

Drug Profile

Epoetin beta - Chugai

Alternative Names: EPOCH; Epogin; Marogen

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Wyeth
  • Developer Chugai Pharmaceutical; Roche
  • Class Antianaemics; Colony-stimulating factors; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaemia
  • Discontinued Chemotherapy-induced anaemia

Most Recent Events

  • 12 Apr 2012 Discontinued - Preregistration for Chemotherapy-induced anaemia in Japan (SC)
  • 30 Sep 2011 The Pharmaceutical Affairs Subcommittee of the Pharmaceutical Affairs and Food Sanitation Council recommends against approval of epoetin beta for Chemotherapy-induced anaemia in Japan
  • 25 Jun 2011 FDA modifies dosage guidelines for Erythropoiesis-Stimulating Agents in patients with chronic kidney disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top